Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more
Green Cross Lab Cell Corporation (144510) - Total Liabilities
Latest total liabilities as of September 2025: ₩134.23 Billion KRW
Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has total liabilities worth ₩134.23 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Green Cross Lab Cell Corporation - Total Liabilities Trend (2015–2024)
This chart illustrates how Green Cross Lab Cell Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Green Cross Lab Cell Corporation Competitors by Total Liabilities
The table below lists competitors of Green Cross Lab Cell Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inogen Inc
NASDAQ:INGN
|
USA | $109.83 Million |
|
KENGIC Intelligent Technology Co. Ltd. A
SHG:688455
|
China | CN¥2.44 Billion |
|
Limes Schlosskliniken AG
XETRA:LIK
|
Germany | €20.16 Million |
|
C6K0
F:C6K0
|
Germany | €33.55 Million |
|
MN Holdings Berhad
KLSE:0245
|
Malaysia | RM214.19 Million |
|
LITALICO Inc.
F:9N0
|
Germany | €26.72 Billion |
|
Imperial Metals Corporation
PINK:IPMLF
|
USA | $808.45 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Green Cross Lab Cell Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Green Cross Lab Cell Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Green Cross Lab Cell Corporation (2015–2024)
The table below shows the annual total liabilities of Green Cross Lab Cell Corporation from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩120.56 Billion | -2.53% |
| 2023-12-31 | ₩123.69 Billion | -10.42% |
| 2022-12-31 | ₩138.07 Billion | +2.60% |
| 2021-12-31 | ₩134.57 Billion | +360.97% |
| 2020-12-31 | ₩29.19 Billion | +21.56% |
| 2019-12-31 | ₩24.02 Billion | +151.56% |
| 2018-12-31 | ₩9.55 Billion | +35.76% |
| 2017-12-31 | ₩7.03 Billion | +9.59% |
| 2016-12-31 | ₩6.42 Billion | -18.81% |
| 2015-12-31 | ₩7.90 Billion | -- |